Genetic variability of hepatitis B virus and response to antiviral therapy

Antiviral Therapy

Volumn 13, Issue 5, 2008, Pages 613-624

  Liu, Chun Jen ^a   Kao, Jia Horng ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; CORE PROTEIN; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TELBIVUDINE; THYMOSIN ALPHA1; VIRUS PROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; DRUG RESPONSE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; RISK ASSESSMENT; SEROCONVERSION; TREATMENT DURATION; VIRAL GENETICS; VIRUS CORE;

ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; TREATMENT OUTCOME; VARIATION (GENETICS);

EID: 49949094294     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Kao JH, Chen DS. Global control of hepatitis B virus. Lancet Infect Dis 2002; 2:395-403.
2. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993; 262:369-370.
3. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:1733-1745.
4. Hepatitis B fact sheet WHO/204. Revised October 2000. (Updated October 2000. Accessed 7 July 2008.) Available from www.who.int/inf-fs/en/ fact204.html
5. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118:554-559.
6. Orito E, Mizokami M, Sakugawa H, et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Hepatology 2001; 33:218-223.
7. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122:1756-1762.
8. Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002; 123:1848-1856.
9. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33:998-1002.
10. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002; 36:1425-1430.
11. Kao JH, Liu CJ, Chen DS. Hepatitis B viral genotypes and lamivudine resistance. J Hepatol 2002; 36:303-304.
12. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38:1267-1273.
13. Akuta N, Suzuki F, Kobayashi M, et al. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 2003; 38:315-321.
14. Zollner B, Petersen J, Schroter M, Laufs R, Schoder V, Feucht HH. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 2001; 357:934-935.
15. Zollner B, Petersen J, Puchhammer-Stockl E, et al. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 2004; 39:42-50.
16. Westland C, Delaney W 4th, Yang H, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 2003; 125:107-116.
17. Sumi H, Yokosuka O, Seki N, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003; 37:19-26.
18. Yuen ME, Wong DK, Sablon E, et al. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther 2003; 8:531-534.
19. Orito E, Ichida T, Sakugawa H, et al. Geographic distribution of hepatitis B virus. (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 2001; 34:590-594.
20. Kao JH, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 2002; 40:1207-1209.
21. Kao JH. Hepatitis B viral genotypes: Clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002; 17:643-650.
22. Hou J, Schilling R, Janssen HLA. Molecular characteristics of hepatitis B virus genotype A confer a higher response to interferon treatment. J Hepatol 2001; 34 Suppl 1:15.
23. Yu MW, Yeh SH, Chen PJ, et al. Genotype and DNA levels of hepatitis B virus and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2005; 97:265-272.
24. Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 1999; 179:775-882.
25. Kao JH, Chen DS. Hepatitis B virus genotypes and hepatocellular carcinoma in Japan: Reply. Gastroenterology 2001; 120:1564-1565.
26. Kao JH. Clinical relevance of hepatitis B viral genotypes: a case of déjà vu? J Gastroenterol Hepatol 2002; 17:113-115.
27. Kao JH, Chen DS. Clinical relevance of hepatitis B virus genotypes Ba and Bj in Taiwan. Gastroenterology 2003; 125:1916-1917.
28. Liu CJ, Huang WL, Chen PJ, Lai MY, Kao JH, Chen DS. End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B. World J Gastroenterol 2004; 10:3574-3578.
29. Chu CJ, Keeffe EB, Han SH, et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003; 125:444-451.
30. Akuta N, Kumada H. Influence of hepatitis B virus genotypes on the response to antiviral therapies. J Antimicrob Chemother 2005; 55:139-142.
31. Tanaka Y, Hasegawa I, Kato T, et al. A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. Hepatology 2004; 40:747-755.
32. Ni YH, Chang MH, Wang KJ, et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology 2004; 127:1733-1738.
33. Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53:1494-1498.
34. Chan HL, Wong ML, Hui AY, et al. Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. World J Gastroenterol 2003; 9:2695-2697.
35. Zollner B, Petersen J, Schafer P, et al. Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment. Clin Infect Dis 2002; 34:1273-1277.
36. Kao JH, Chen PJ, Lai MY, Chen DS. Clinical and virological aspects of blood donors infected with hepatitis B virus genotypes B and C. J Clin Microbiol 2002; 40:22-25.
37. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124:327-334.
38. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol 2004; 72:363-369.
39. Chen JD, Liu CJ, Lee PH, et al. Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2004; 2:64-71.
40. Buti M, Cortina M, Valdes A, Jardi R, Rodriguez-Frias F, Esteban R. Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine? J Hepatol 2002; 36:445-446.
41. Kuwahara R, Kumashiro R, Murashima S, et al. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy. J Med Virol 2004; 72:26-34.
42. Chen BF, Chen PJ, Jow GM, Liu CJ, Kao JH, Chen DS. High prevalence of mixed genotype infections in hepatitis B virus infected intravenous drug users. J Med Virol 2004; 74:536-542.
43. Liu CJ, Kao JH, Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liver Int 2005; 25:1097-1107.
44. Lin CL, Kao JH. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci 2008; 15:137-145.
45. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000; 31:1037-1044.
46. Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 2006; 130:1153-1168.
47. Liu CJ, Chen BF, Chen PJ, et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis 2006; 193:1258-1265.
48. Liu CJ, Lai MY, Chao YC, et al. Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study. Hepatology 2006; 43:742-749.
49. Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. Evolution of hepatitis B virus in an acute hepatitis B patient co-infected with genotypes B and C. J Gen Virol 2006; 87:39-49.
50. Lin CL, Kao JH, Chen BF, Chen PJ, Lai MY, Chen DS. Application of hepatitis B virus genotyping and phylogenetic anal in intrafamilial transmission of gepatitis B virus. Clin Infect Dis 2005; 41:1576-1581.
51. Liu CJ, Kao JH. Subgenotypes of hepatitis B virus genotype C in Taiwan. J Infect Dis 2005; 192:1308-1309.
52. Liu CL, Liao LY, Wang CS, et al. Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. Liver Int 2005; 25:564-570.
53. Liu CJ, Chen BF, Chen PJ, et al. Role of hepatitis B virus precore/core promoter mutations and serum viral load on non-cirrhotic hepatocellular carcinoma: a case control study. J Infect Dis 2006; 194:594-599.
54. Flink HJ, Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HLA. Treatment with peg-interferon alfa-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101:297-303.
55. Yang HI, Chen PJ, Yeh SH, et al. Risk of hepatocellular carcinoma associated with genotypes and mutants of hepatitis B virus: a community-based prospective cohort study. J Hepatol 2006; 44 Suppl 2:27A.
56. Liu CJ, Kao JH. Core promoter mutations of hepatitis B virus and hepatocellular carcinoma: the story beyond A1762T/G1764A mutations. J Gastroenterol Hepatol 2008; 23:347-350.
57. Cooksley G, Manns M, Lau GKK, Liaw YF, Marcellin P, Chow WC. Effect of genoty and other baseline factors on response to peginterferon alra-2a (40KD) (Pegasys) in HBeAg-positive chronic hepatitis B: Results from a large, randomized study. J Hepatol 2005; 42 Suppl 2:30.
58. Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus geno pe dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54:1009-1013.
59. Hadziyannis S, Lau GKK, Marcellin P, Piratvisuth T, Cooksley G, Bonino, F. Sustained HBsAg seroconversion in patients with chronic hepatitis B treated with peginterferon alfa-2a (40KD) (Pegasys). J Hepatol 2005; 42 Suppl 2:178.
60. Suzuki F, Tsubota A, Arase Y, et al. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 2003; 46:182-189.
61. Lurie Y, Manus MP, Gish RG, Chang TT, Yurdaydin C Lai CL. The efficacy of entecavir is similar regardless of disease-related baseline subgroups in treatment of nucleoside-naive, HBeAg(+) and HBeAg(-) patients with chronic hepatitis B. J Hepatol 2005; 42 Suppl 2:184.
62. Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther 2008; 13:211-220.
63. Chu RH, Ma LX, Wang G, Shao LH. Influence of HLA-DRB1 alleles and HBV genotypes on interferon-alpha therapy for chronic hepatitis B. World J Gastroenterol 2005; 11:4753-4757.
64. Zhao H, Kurbanov F, Wan MB, et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis 2007; 44:541-548.
65. Zhang X, Zoulim F, Habersetzer F, Xiong S, Trepo C. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HB e antigen negative chronic hepatitis B. J Med Virol 1996; 48:8-16.
66. Chien RN, Lin CY, Yeh CT, Liaw YF. Hepatitis B virus genotype B is associated with better response to thymosin alphal therapy than genotype C. J Viral Hepat 2006; 13:845-850.
67. Thompson AJ, Ayres A, Yuen L, et al. Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J Gastroenterol Hepatol 2007; 22:1078-1085.
68. Hou J, Schilling R, Janssen HL, et al. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. J Med Virol 2007; 79:1055-1063.
69. Okamoto H, Tsuda F, Sakugawa H, et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 1988; 69:2575-2583.
70. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994; 198:489-503.
71. Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002; 83:2059-2073.
72. Stuyver L, De Gendt S, Van Geyt C, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000; 81:67-74.
73. Asahina Y, Izumi N, Uchihara M, et al. Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C. J Hepatol 2003; 39:1063-1069.
74. Hannoun C, Horal P, Krogsgaard K, Lindh M, INTERPRED Study Group. Mutations in the X region and core promoter are rare and have little impact on response to interferon therapy for chronic hepatitis B. J Med Virol 2002; 66:171-178.
75. Marrone A, Zampino R, Luongo G, Utili R, Karayiannis P, Ruggiero G. Low HBeAg serum levels correlate with the presence of the double A1762T/ G1764A core promoter mutation and a positive response to interferon in patients with chronic hepatitis B virus infection. Intervirology 2003; 46:222-226.
76. Erhardt A, Reineke U, Blondin D, et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000; 31:716-725.
77. Kanai K, Kako M, Aikawa T, et al. Core promoter mutations of hepatitis B virus for the response to interferon in e antigen-positive chronic hepatitis B. Am J Gastroenterol 1996; 91:2150-2156.
78. Woolf SH. Review articles and disclosure of methods. Am J Prev Med 1991; 7:53-54.
79. Liu CJ, Chen PJ, Lai MY, et al. Lack of interferon sensitivity-determining region in the genome of hepatitis B virus genotype Ba. Antivir Ther 2004; 9:895-903.
80. Lok AS, Akarca US, Greene S. Predictive value of precore hepatitis B virus mutations in spontaneous and interferon-induced hepatitis B e antigen clearance. Hepatology 1995; 21:19-24.
81. Brunetto MR, Giarin M, Saracco G, et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993; 105:845-850.
82. Aikawa T, Kanai K, Kako M, et al. Interferon-alpha 2a for chronic hepatitis B with e antigen or antibody: comparable antiviral effects on wild-type virus ond precore mutant. J Viral Hepat 1995; 2:243-250.
83. Kanai K, Kako M, Aikawa T, et al. Core promoter mutations of hepatitis B virus for the response to interferon in e antigen-positive chronic hepatitis B. Am J Gastroenterol 1996; 91:2150-2156.
84. Kako M, Kanai K, Aikawa T, et al. Response to interferon-alpha 2a in patients with e antigen-negative chronic hepatitis B. J Clin Gastroenterol 1997; 25:440-445.
85. Shindo M, Hamada K, Koya S, Sokawa Y, Okuno T. The clinical significance of core promoter and precore mutations during the natural course and interferon therapy in patients with chronic hepatitis B. Am J Gastroenterol 1999; 94:2237-2245.
86. Kuwahara R, Kumashiro R, Murashima S, et al. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy. J Med Virol 2004; 72:26-34.
87. Shin JW, Chung YH, Choi MH, et al. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy. J Gastroenterol Hepatol 2005; 20:844-849.
88. Chen CH, Lee CM, Lu SN, et al. Comparison of sequence changes of precore and core promoter regions in HBeAg-postive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy. J Hepatol 2006; 44:76-82.
89. Yuen MF, Sablon E, Libbrecht E, et al. Significance of viral load, core promoter/precore mutations and specific sequences of porlymerase gene in HBV-infected patients on 3-year lamivudine treatment. Antivir Ther 2006; 11:779-786.
90. Fukai K, Zhang KY, Imazeki F, Kurihara T, Mikata R, Yokosuka O. Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase. J Viral Hepat 2007; 14:661-666.
91. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25:472-489.
92. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539.
93. de Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B consensus statement (long version). 13-14 September 2002 Geneva, Switzerland. J Hepatol 2003; 39 Suppl 1:S3-S25.
94. Dooley JS, Davis GL, Peters M, Waggoner JG, Goodman Z, Hoofnagle JH. Pilot study of recombinant human alpha-interferon for chronic type B hepatitis. Gastroenterology 1986; 90:150-157.
95. Hoofnagle JH, Peters M, Mullen KD, et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95:1318-1325.
96. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-inteferon treatment in patients with hepatitis B e antigen positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119:312-323.
97. Shaw T, Locarnini S. Entecavir for the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther 2004; 2:853-871.
98. Lai CL, Ching CK, Tung AK, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997; 25:241-244.
99. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256-1263.
100. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119:172-180.
101. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005; 365:123-129.
102. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10:298-305.
103. Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alfa-2a, lamivudine and the two combined for HBeAg negative chronic hepatitis B. Gut 2007; 56:699-705.
104. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576-2588.
105. Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2008; 47:447-454.
106. Lok AS, Hussain M, Cursano C, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000; 32:1145-1153.
107. Lin CL, Liao LY, Wang CS, et al. Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudin therapy. Liver Int 2004; 24:9-15.